Senesco Technologies Investor Presentation

1. Senesco Technologies, Inc.
Changing Cancer Therapy
Leslie J. Browne, Ph.D.
President & CEO
October 23rd, 2013

2. Safe Harbor Statement
Certain statements included in this presentation are forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from such
statements expressed or implied herein as a result of a variety of factors, including, but not limited to:
the Company’s ability to recruit patients for its clinical trial, the ability of the Company to consummate
additional financings; the development of the Company’s gene technology; the approval of the
Company’s patent applications; the successful implementation of the Company’s research and
development programs and collaborations; the success of the Company's license agreements; the
acceptance by the market of the Company’s products; the timing and success of the Company’s
preliminary studies, preclinical research and clinical trials; competition and the timing of projects and
trends in future operating performance, the Company’s ability to comply with the continued listing
standards of the NYSE/MKT, as well as other factors expressed from time to time in the Company’s
periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press
release should be read in conjunction with the Company’s periodic filings with the SEC. The forwardlooking statements contained herein are made only as of the date of this press release, and the
Company undertakes no obligation to publicly update such forward-looking statements to reflect
subsequent events or circumstances.
2

3. About Senesco
 Founded 1998
 Located Bridgewater, NJ
 9 employees
 Focused on cancer therapeutics
 Listed on OTC QB as SNTI

4. Senesco’s Gene Regulation
Platform Technology
 Senesco Technologies is a clinical stage biotech company specializing
in cancer therapeutics
 Our proprietary gene regulation technology has demonstrated the
ability to eliminate cancerous cells and protect healthy cells from
premature death
 The company is running a Phase 1b/2a trial with a product that treats
B-cell cancers (which include multiple myelomia and non-Hodgkins Bcell lymphomas)
 Trial sites include the Mayo Clinic and the Fred Hutchinson Cancer
Research Center
 The technology was developed over the last 15 years through the
discovery that the genetic pathway for cell growth control, targeted by
Senesco, is common to both plants and humans

5. Stock Basics & Financial Summary
Ticker:
Stock Exchange:
Recent Price:
Cash on Hand as of June 30, 2013, as adjusted
Current burn rate per quarter
Revolving secured credit line
SNTI
OTC QB
$3.30
$3,200,000
$1,200,000
$2,300,000
Capitalization Table as of October 21, 2013
Common Stock Outstanding
Preferred Stock
Options
Warrants Outstanding
Fully Diluted
3,067,000
232,000
278,000
283,000
3,860,000
5

6. Senesco’s Platform
A novel therapeutic
approach based on gene
regulation
6

7. Senesco’s Platform Targets
B-cell Cancers
 Multiple myeloma is an incurable cancer
of plasma cells – “B-cell” cancer
 ~65,000 patients in the US
 Median survival time is 2½ to 5 years
 Diffuse large B-cell lymphoma (DLBCL)
 Most commonly diagnosed lymphoma
 ~120,00 patients in the US
 ~ 50% of patients unresponsive to standard
therapy
 Mantle cell lymphoma (MCL)
All orphan drug indications
 ~30,000 patients in the US
 Aggressive tumor with poor outcomes
7

8. Multiple Myeloma: Large Market &
High Unmet Medical Need
Company
Drug®
2012 Sales
Takeda
Velcade
$2,100 MM
Celgene
Revlimid
$3,770 MM
Celgene
Thalomid
$387 MM
Onyx
Kyprolis
~$250 MM (1st year)
Multiple myeloma market projected at $6 billion by 2018

9. Turning on a Normal Regulatory
Process
 Lysine Protein – need to turn up
 Activates programmed cell death (apoptosis)
 Hypusine Protein – need to turn down
 Stimulates cell growth
 Senesco’s drug reprograms the cells to
recognize the death message by modulating
the levels of both proteins
9

10. Proteins Regulate Cell Growth
and Death
These two proteins act as a biological
switch to promote cell death or survival
amino
acid
Lysine
Hypusine
F5A
protein
protein
protein
Lysine form
stimulates cell death
aka “apoptosis”
amino
acid
Hypusine form
stimulates survival
 Lysine and hypusine proteins control cell death and
growth
10

11. Senesco’s Drug Candidate
Changes Levels of Both Proteins
Therapeutic Strategy: Our drug down-regulates the
growth message and up-regulates the death message so
inducing cancer cells to die
amino
acid
Lysine
Arginine
Hypusine
amino
acid
switch
Lysine form
Arginine form
stimulates cell death
aka “apoptosis”
F5A
protein
protein
protein
Hypusine form
promotes survival
 Replace hypusine with arginine
 Switch from survival to cell death
11

12. Our Drug Uses Nanotechnology
1. RNAi suppresses pro-survival
hypusine form
2. DNA plasmid makes stable death
message under control of B-cell
specific promoter
3. Polymer (PEI) forms nanoparticle
to protect RNA and DNA and
deliver death message to target
SNS01-T nanoparticle
~ 40 x 70 nM
12

13. Pre-Clinical Results

14. Efficacy in Cancer Cell Lines
and In Vivo Models
 Our drug platform modulates and has broad
activity in most cancer cell lines tested in vitro
 Efficacy in multiple in vivo disease models
including melanoma (B16-F0) and lung (A549)
cancer*
 Efficacy in blood cancer models in mice
 85-95% growth inhibition in B-Cell cancers
 Synergy with bortezomib and lenalidomide
* Gene Ther Mol Biol 12, 207-218 (2008)
14

15. >90% Inhibition of Human Multiple
Myeloma Tumors in Mice
* p < 0.05 (n = 3)
** p < 0.01 (n = 3)
*** p < 0.001 (n = 3)
Last Injection
*
*** ***
** ***
**
**
*** ***
*** ***
***
***
15

16. Tumor Growth Control
Human multiple myeloma tumors reduced
up to 95% by SNS01-T treatment

17. Significantly Improved Survival
in Multiple Myeloma Model
EX31-RPMI 8226:Survival proportions
RPMI 8226
Multiple Myeloma
Tumor Growth Inhibition
102 Day Survival
100
***
90
Percent survival
80
**
70
60
50
End of treatment
40
1. Lenalidomide 50mg
20% (p < 0.05)
2. SNS01-T 0.375mg
60% (p < 0.01)
3. SNS01-T+ LEN 50
100% (p < 0.001)
**
30
20
10
0
0
10
20
30
40
50
60
70
80
90
100
110
Days of Treatment
Control Nanoparticle
SNS01-T
LEN 50
SNS01-T +LEN 50
* p < 0.05; ** p < 0.01; *** p < 0.001
(compared to control group; Logrank test)
 SNS01-T is
better alone
 Combined
even better
17

18. Clinical Trial Status

19. Phase 1b/2a B-cell Cancer Study
Design
 Open-label, multiple-dose, dose-escalation
 Twice-weekly IV infusions for 6 weeks
Endpoints
 Safety and tolerability
 Pharmacokinetics
 Tumor response
 Time to relapse or progression
Clinical Sites
 Mayo Clinic, U Arkansas, Hackensack UMC, U West
Virginia, Seattle Cancer Care Alliance
19

20. Phase 1b/2a Interim Results
from Groups 1 & 2
 10 patients enrolled in groups 1 and 2
 Good tolerability and stable disease at lowest doses
 2 patients had stable disease at weeks 3 & 6
 1 patient remained stable 4 weeks post dosing
 No drug-related severe adverse events
 No dose-limiting toxicities
20

21. Recruitment Continuing at Next
Dose Level
 Phase 1b/2a group 3 is ongoing at 0.2 mg/Kg
• 0.2 mg/Kg is efficacious dose level in cancer
models in mice
• 3 patients need to be completed
21

22. Clinical Development Plans
 Group 3 results by 4Q-2013
 Topline results of Phase 1b/2a in 1H-2014
 Phase 2 initiation planned for 2H-2014
• Focus on multiple myeloma, mantle and diffuse large
B-cell lymphomas
22

23. Corporate

24. Board of Directors
Harlan W. Waksal, M.D.
Chair, Former COO, Imclone Systems
Christopher Forbes
Vice Chair, Forbes Media, LLC
John N. Braca
Exec Director Controller, Iroko Pharma
Leslie J. Browne, Ph.D.
Pres & CEO, former CEO Pharmacopeia
Warren Isabelle, CFA
Founder, Ironwood Investment Mgmt
Thomas C. Quick
Former Vice Chair, Quick & Reilly/Fleet
David Rector
Principal David Stephen Group
Ruedi Stalder
Former Exec Board Member Credit Suisse
John E. Thompson, Ph.D.
Executive VP, R&D, FRS of Canada
24
Jack Van Hulst
Operating Partner, SK Capital Partners

25. Summary
World-class science and management team
Founder of ImClone, Dr. Harlan Waksal, is
Chairman of the Board
Near-term clinical trial results from Phase 1b/2a
study
6 billion dollar opportunity for multiple myeloma
alone
Many additional applications in solid tumors,
inflammation and Alzheimers
25

26. Corporate Information
Senesco Technologies, Inc.
721 Route 202/206, Suite 130
Bridgewater, NJ 08807
Phone: 908-864-4444
www.senesco.com
OTCQB: SNTI
IR: RedChip Companies, Inc
Dave Gentry
Phone: 800-RED-CHIP (733-2447), ext.104
Email: info@redchip.com
26